loader from loading.io

Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities

The ONS Podcast

Release Date: 07/04/2025

Episode 380: Colorectal Cancer Survivorship Considerations for Nurses show art Episode 380: Colorectal Cancer Survivorship Considerations for Nurses

The ONS Podcast

  “One powerful, overlooked aspect of colorectal cancer survivorship is the emotional and identity transformation that our survivors undergo—and really how little space is given in the clinical arena for that. No one really talks about this ‘invisible recovery.’ Facing mortality can lead to prolonged changes is values, relationships, and life goals. And these experiences aren’t captured in lab results or imaging scans, but they really shape how survivors live, love, and heal and continue with their lives,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal...

info_outline
Episode 379: Pharmacology 101: BCR-ABL1 Inhibitors show art Episode 379: Pharmacology 101: BCR-ABL1 Inhibitors

The ONS Podcast

“All of these TKIs [tyrosine kinase inhibitors] inhibit BCR-ABL1 in some way, shape, or form. When BCR-ABL1 is mutated, it has uncontrolled tyrosine kinase activity, leading to rapid cell proliferation. When we then inhibit that BCR-ABL1 that’s been mutated, we disrupt this abnormal signaling pathway that drives CML [chronic myeloid leukemia] cell proliferation and survival, ultimately leading to decreased cancer cell growth, increased apoptosis or cell death, and potentially inducing a disease remission,” Samantha Maples, PharmD, BCOP, clinical pharmacy specialist supervisor for...

info_outline
Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer show art Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer

The ONS Podcast

“She’s triple negative and has a very, very aggressive tumor. Instead of going on spring break that year, she sat in our chemo room and got chemo. Her friends from college are good to try to keep her involved and try to surround her and encourage her, but they’re right now in very, very different spots in their lives. She’s fighting for her life; her friends are fighting for the grade they get in a class—and that’s different,” ONS member Kristi Orbaugh, MSN, NP, AOCN®, AOCNP®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer,...

info_outline
Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures show art Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures

The ONS Podcast

“Policies help make sure that we’re giving patients the right education and discharge instructions. Radiation doesn’t end when the syringe is empty. Patients go home with potential radioactive exposure. They need to know how to protect their families, what precautions to take, and what healthcare providers can do if something goes wrong—like a spill, extravasation, or even a pregnant staff member who’s involved in the care. This isn’t just a documentation exercise. It’s about making sure every part of the system speaks the same language when it comes to safety, handling, and...

info_outline
Episode 376: ONS 50th Anniversary: The Science Behind the History of Nursing Burnout and Compassion Fatigue show art Episode 376: ONS 50th Anniversary: The Science Behind the History of Nursing Burnout and Compassion Fatigue

The ONS Podcast

“At least some of the answer to these issues of compassion fatigue and burnout have to do making our practice environments the very, very best they can be so that nurses and other clinicians can really connect and care for patients in the ways that they want to be able to do that—and the patients need them to be able to do. I think there’s a lot that is here already and will be coming, and I feel pretty optimistic about it,” ONS member Anne Gross, PhD, RN, NEA-BC, FAAN, senior vice president for patient care services and chief nursing officer at Dana-Farber Cancer Institute in...

info_outline
Episode 375: Pharmacology 101: VEGF Inhibitors show art Episode 375: Pharmacology 101: VEGF Inhibitors

The ONS Podcast

“We’re really using these in many, many types of malignancies. But you can see this class of drug, these monoclonal antibodies, the small molecule inhibitors, being used in colorectal cancer, ovarian cancer, renal cell carcinoma, brain cancers, hepatocellular, non-small cell lung cancer, gynecologic malignancies, so lots of different types of cancers where we’re seeing these drugs used,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of...

info_outline
Episode 374: Colorectal Cancer Treatment Considerations for Nurses show art Episode 374: Colorectal Cancer Treatment Considerations for Nurses

The ONS Podcast

“Colorectal cancer treatment is not just about eliminating a disease. It’s about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment’s just not about protocols. It’s about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James...

info_outline
Episode 373: Biomarker Testing in Prostate Cancer show art Episode 373: Biomarker Testing in Prostate Cancer

The ONS Podcast

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a...

info_outline
Episode 372: Pharmacology 101: Proteasome Inhibitors show art Episode 372: Pharmacology 101: Proteasome Inhibitors

The ONS Podcast

“The proteasome itself, it really helps us unfold or get rid of misfolded proteins or degradations of different cells. We used to have garbage disposals in our sinks, and we used to put food product in there. If your garbage disposal is clogged, then everything backs up. So that’s kind of what’s really going on in the cell itself, is that I’m building up these unnecessary proteins that we should be getting rid of, and it actually causes apoptosis or cell death,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical...

info_outline
Episode 371: ONS 50th Anniversary: ONS’s Rich History of International Work Advances the Future of Global Oncology Nursing show art Episode 371: ONS 50th Anniversary: ONS’s Rich History of International Work Advances the Future of Global Oncology Nursing

The ONS Podcast

“We want to make sure that nurses, have opportunities both in our local communities as well as international communities, to engage in courageous dialog with others who may think or look different than we do and whose culture or language may also be different. The difference is what brings us together and allows us to have more of this tapestry of what we are about—ensuring that we advance health for all and that we are able to move forward together,” ONS member Ashley Leak-Bryant, PhD, RN, OCN®, professor at University of North Carolina (UNC) at Chapel Hill, told Darcy Burbage, DNP,...

info_outline
 
More Episodes

“The five-year relative survival rate for localized, or cancer that is confined to the colon or the rectum, is 91% for colon cancer and 90% for rectal cancer. Distant, metastasized to other organs—the five-year survival rate is 13% for colon and 18% for rectal cancer. So that really shows you the huge difference in screening and where screening can come in and make better outcomes,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer screening.

Music Credit: “Fireflies and Stardust” by Kevin MacLeod

Licensed under Creative Commons by Attribution 3.0 

Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 4, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Learning outcome: Leaners will report an increase in knowledge related to colorectal screening, early detection, and disparities.

Episode Notes

To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.

To provide feedback or otherwise reach ONS about the podcast, email [email protected].

Highlights From This Episode

“Interestingly, recent studies suggest that starting screening even earlier than 45, such as age 40, could significantly reduce mortality and incidence rates, especially as colorectal cancer is rising among younger adults.” TS 2:42

“[Artificial intelligence]-enhanced screening tools are also being developed to improve sensitivity, reduce turnaround time, and enable real-time monitoring of disease progression. These innovations aim to make screening more accessible and accurate, especially in our underserved populations. So there’s a huge impact on early detection.” TS 4:07

“Those with multiple chronic conditions or limited mobility may be less likely to complete screening, and those results may be harder to interpret. I mentioned a little bit earlier about our underserved or minority populations. Those barriers such as limited health literacy, lack of insurance, and cultural stigma can reduce screening uptake and ultimately follow-through.” TS 12:25

“Patient navigation programs—this is where we have trained navigators to help patients schedule appointments, understand procedures, and ultimately overcome some of these logistical hurdles. These have actually been shown to significantly boost screening rates. Also, those mailed stool-based-test kits—sending those kits directly to a patient home, especially with a personalized letter from a provider to add that extra little touch, has proven effective in increasing participation.” TS 21:29

“Our screening can detect cancer before symptoms appear and even identify precancerous polyps, which can be removed to prevent cancer altogether. Studies actually show that regular screening can reduce colorectal cancer mortality by up to 35% and the incidence of advanced-stage disease by nearly 30%. Just another reason why screening really does matter.” TS 25:53

“Evaluating our implicit bias, especially in something as critical as colorectal cancer, requires both introspection and instructional supports. One way of doing this is by auditing your practice patterns, really looking at reviewing your own screening recommendations and follow-up rates across different patient demographics. So are there certain groups that are less likely to be offered a colonoscopy? I think some of us may have an implicit bias—you see a patient; you’re like, ‘There’s no way they’re going to agree to that, so I’m just not going to offer it.’ Where we don’t offer it, they don’t have that opportunity to decline that. That can lead to further delay. And those patterns can reveal a bias in action.” TS 28:18